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Abstract
Background: Hereditary Angioedema (HAE) is a rare, autosomal dominant (AD) disorder caused by a C1 esterase 
inhibitor (C1-inh) deficiency or qualitative defect. Treatment of HAE in many parts of the world fall short and certain 
items need to be addressed in future guidelines.
Objective: To identify those individuals who should be on long-term prophylaxis for HAE. Additionally, to determine if 
prodromal symptoms are sensitive and specific enough to start treatment with C-1 INH and possibly other newly 
approved therapies. Also, to discuss who is appropriate to self-administer medications at home and to discuss training 
of such patients.
Methods: A literature review (PubMed and Google) was performed and articles published in peer-reviewed journals, 
which addressed HAE prophylaxis, current HAE treatments, prodromal symptoms of HAE and self-administration of 
injected home medications were selected, reviewed and summarized.
Results: Individuals whom have a significant decrease in QOL or have frequent or severe attacks and who fail or are 
intolerant to androgens should be considered for long-term prophylaxis with C1INH. Prodromal symptoms are 
sensitive, but non-specific, and precede acute HAE attacks in the majority of patients. Although the treatment of 
prodromal symptoms could lead to occasional overtreatment, it could be a viable option for those patients able to 
adequately predict their attacks. Finally, self-administration, has been shown to be feasible, safe and effective for 
patients who require IV therapy for multiple other diseases to include, but not limited to, hemophilia.
Conclusions: Prophylactic therapy, treatment at the time of prodromal symptoms and self-administration at home all 
should allow a reduction in morbidity and mortality associated with HAE.
Background
Hereditary angioedema (HAE) is a rare autosomal domi-
nant disease with significant mortality and morbidity.
H A E  i n v o l v e s  a n  a b s e n t  o r  d y s f u n c t i o n a l  C - 1  e s t e r a s e
inhibitor (C1-inh), which is a multifactorial protease
involved in the control of vascular permeability. C1-inh is
involved in the regulation of the complement, contact,
coagulation and fibrinolytic systems. It is the main inhibi-
tor of C1r and C1s of the complement system. C1-inh is
also a major inhibitor of factor XII and kallikrein of the
contact system, and to a lesser extent of factor XI and tis-
sue-type plasminogen. Finally, C1-inh controls the pro-
duction of vasoactive peptides, of which bradykinin has
been significantly implicated in the development of
angioedema [1,2].
Clinically, HAE is characterized by acute attacks of
painless, non-pitting, non-pruritic swelling of the skin
and subcutaneous tissues. It affects approximately 1 in
10000 to 1 in 50000 individuals of all races and ethnici-
ties. Due to its significant morbidity and its 15-33% mor-
tality, usually due to laryngeal edema and subsequent
asphyxiation, some individuals require long term prophy-
laxis in order to prevent subsequent attacks [3-5]. Cur-
rently, medications used for prophylaxis largely revolve
around the androgen, danazol, although prophylactic
treatment with C1 esterase inhibitor is now available.
Danazol, though effective in decreasing the severity and
frequency of attacks, has numerous side effects, which
often leads to its discontinuation or patient noncompli-
ance [4,5]. However, identifying potential patients who
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would benefit from a long-term prophylaxis regimen is
imperative to decrease the morbidity and mortality asso-
ciated with HAE.
Some of the major concerns associated with the new
recently approved and soon to be approved prophylactic
medications is not only expense, but also how the drug is
administered. Currently, C1-inh is available only via IV
administration and its administration by a health care
provider at a health care facility would be time consum-
ing and inconvenient for the patient. In order to regain
flexibility and lead to an increased quality of life for the
patient, it would be prudent to determine who would be a
candidate for self-administration of C1-inh and other IV
medications. This manuscript will also review when and
for whom self-administration would be a feasible, safe
and effective option for prophylaxis and on demand with
C1-inh. This is especially important since early therapy
reduces the burden of disease.
Up until recently, when a patient experienced an attack,
the treatment has been supportive care, hydration, pain
relief, and close observation. FFP has been utilized suc-
cessfully, but a small amount of risk is possible [6]. In Oct
2009 human C1-inh concentrate given at a dose of 20 U/
kg was found to be safe, well tolerated and efficacious in
diminishing time to relief onset when giving during acute
facial or abdominal HAE attacks [7]. This treatment,
although it ameliorates symptoms rapidly, still has multi-
ple disadvantages for the patient if used after the symp-
toms of an acute attack start and many recommend
starting "on demand therapy (ODT)" at the time of pro-
dromal symptoms to decrease morbidity and possible
mortality associated with HAE [6,7]. We will expand on
this concept of prodromal symptoms and their signifi-
cance regarding treatment in the text of this manuscript.
Methods
A literature review (utilizing PubMed, OVID and Google)
was performed using the following terms to search for
individuals who should be treated with long-term pro-
phylaxis: "long term prophylaxis and hereditary angioe-
dema." Additionally, the terms prodromal symptoms,
hereditary angioedema and C1-inh were used to search
for literature regarding the sensitivity and specificity of
prodromal symptoms and their use in treating an immi-
nent attack. F inally , PubMed and Google were used to
search for individuals deemed fit to self-administer medi-
cations: "self-administration of C-1 esterase inhibitor and
HAE."
Results
Who is a suitable candidate for long-term prophylaxis with 
C-1 esterase inhibitor?
The individuals deemed candidates for long-term pro-
phylaxis were identified in a previous literature review
and those situations are listed in appendix 1[5]. Addition-
ally, patients who fail, have adverse reactions to or are
unable to tolerate androgen therapy should be considered
for prophylaxis with C1-inh.
Currently, the medications used for prophylaxis can
include androgens, antifibrinolytics, and C-1esterase
inhibitor. It is likely that the short half life associated with
the bradykinin receptor antagonist (icatabant) and kal-
likrein inhibitor (ecallantide) will limit they use as pro-
phylactic therapy. The androgen, danazol, is the current
medication of choice for prophylaxis due to its cost effec-
tiveness and ease of administration. However, danazol
has numerous side effects that may lead to the discontin-
uation of the drug and/or noncompliance in some
patients.
Danazol, a synthetic derivative of ethisterone, is effec-
tive in decreasing the severity and frequency of attacks in
patients with HAE [4]. However, due to the numerous
side effects, which include weight gain, virilization, men-
strual irregularities, depression, headache and abnormal
liver function tests, it is often poorly tolerated. In a long-
term study of 118 patients with HAE, 30 (25.4%) patients
had to discontinue the drug due to these adverse effects
[4]. Not only does danazol often lead to the intolerable
side effects noted above it has also been shown to have a
negative effect on lipid profiles. This unfavorable lipid
profile may also exist in the setting of increased blood
pressure in some patients on long-term danazol therapy
and a subsequent increased risk of cardiac and vascular
disease [8]. Another frequent adverse event is the
increase risk of liver disease, including hepatic cell necro-
sis, cholestasis and even to the development of hepatocel-
lular adenoma and hepatocellular carcinomas. The
adverse effects are dose related with increased dosages
being associated with increased adverse effects [4,6,8].
Appendix 2 demonstrates the adverse effects of androgen
therapy [6].
In addition to androgen therapy, other medications
have been investigated as prophylactic agents for HAE.
Icatibant, a specific antagonist of bradykinin B2 recep-
tors, is currently approved in Europe for the treatment of
acute HAE attacks. However, it is not suitable as a candi-
date for prophylaxis due to its relatively short half-life of
1.2-1.5 hours with SQ administration [9].
Ecallantide is an inhibitor of the protein kallikrein and
as of Nov 2009 has been approved for the use of acute
attacks of HAE in the United States. However, similarly to
icatibant, its use as a prophylactic agent is limited, sec-
ondary to its short half-life, which approximates 2 hours
[4].
Antifibrinolytics, such as epsilon-aminocaproic acid,
has also been used as a prophylactic agent for HAE. It is
used to inhibit the formation of plasmin and fragments of
the Hageman factor, leading to the inhibition of kallikreinDagen and Craig Allergy, Asthma & Clinical Immunology 2010, 6:11
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and bradykinin production [10]. Anti-fibrinolytics have
been used not only in patients with HAE but also to con-
trol bleeding after cardiac surgeries and in other hemato-
logic diseases. Its major side effects include hypotension,
cardiac arrhythmias, rhabdomyolysis, and generation of
thrombi and associated risk of emboli. Because of the side
effect profile, limited effectiveness and need to dose fre-
quently physicians have not utilized this therapy to the
same extend as androgens [11].
In comparison to these agents, plasma derived nano-fil-
tered-C-1 esterase inhibitor, known as Cinryze, has a
half-life of 36-48 hours when administered intravenously
and could lead to significant protection for 72 hours or
greater [12]. However, due to its expense, the need for IV
administration and need to re-dose every 3-4 days sug-
gest it should be used in those with severe disease or in
those that their HAE has a significant impact on their
quality of life.
The use of nano-filtered-C-1 esterase inhibitor (nf-C1-
INH) for prophylaxis has been well received in the USA.
Dosing twice per week seems to be important to limit
break through attacks, but even with twice weekly dosing
acute attacks often occur requiring additional doses of nf-
C1-INH. From personal communications with physicians
prescribing nf-C1-INH most are encouraging patients to
self-treat or be infused by family members. Some have
advocated the use of indwelling central catheters or ports;
h o w e v e r ,  t h e  b e n e f i t s  o f  a  p o r t  n e e d  t o  b e  w e i g h t e d
against the adverse events associated with them. In our
cohort the use of nf-C1-INH infused through a port has
been complicated with thrombi.
Treating at the time of Prodromal Symptoms
Treatment at the time of prodromal symptoms, which
may result in occasional over treatment, but which will
still conserve concentrate and reduce cost when com-
pared to prophylactic therapy, would decrease morbidity
and mortality associated with HAE. Treatment before
any swelling, onset of abdominal pain or throat swelling
would improve quality of life of patients and reduce loss
of productivity. Prior manuscripts by M Prematta and J
Kemp, both published in 2009 in the Proceedings of
Allergy and Asthma, demonstrated that prodromal symp-
toms are a sensitive predictor that an attack may occur in
hours or days, but the exact specificity of prodromal
symptoms for an attack is not known. The most common
identifiable prodromal symptoms include unusual
fatigue, rash on arms or legs and muscle aches. The retro-
spective study, noted above, conducted in 2009 by Pre-
matta et al has already established that prodromal
symptoms can be used as a sensitive measure to predict
an acute attack [7].
This study, utilizing a 4-page survey, was conducted in
order to investigate the reliability with which prodromal
syndromes can be used to identify an imminent attack.
T h e  r e s u l t s ,  d e m o n s t r a t e d  i n  f i g u r e  1  i n d i c a t e  t h a t  3
(6.5%) patients could predict the onset of symptoms 100%
of the time; 23 (50.0%) answered the ability to predict
acute attacks 75% of the time; 4 (8.7%) patients answered
50% of time; and 12 (26.1%) answered 25% of the time.
Only 4 (8.7%) reported not being able to predict the onset
of HAE attacks [7]. Among the patients that remembered
the timing of past prodromes, 20 of 44 (45.5%) patients
reported that the average time of the onset of a prodrome
was less than 24 hours before an HAE attack. Meanwhile,
24 of 44 (54.5%) patients reported that, on average, the
onset of prodromal symptoms developed greater than 24
hours before HAE symptoms initiate. Figure 2 demon-
strates these data [7].
These data support that prodromal symptoms occur
commonly before acute HAE attacks with 87.0% of
patients having had a prodrome before their last HAE
attack, and 95.7% of patients reported having had a pro-
dromal symptom before at least one acute attack in the
past [7]. These data have demonstrated that prodromal
symptoms could indeed be a sensitive measure of pre-
dicting acute HAE attacks and could possibly be used to
initiate therapy before the onset of an acute attack, thus
reducing morbidity and possibly mortality. In addition,
this could lead to a better quality of life and decreased
anxiety for patients with HAE [7].
Who is fit to self-administer C1-inh at home?
The ability of patients to self-administer intravenous C1-
inh at home would allow for greater flexibility, increased
convenience and an increased quality of life, provided
they were able to demonstrate the techniques noted in
appendix 3 [13]. It also would decrease time to treatment
if able to be administered by the patient for an acute
attack, which should lead to a reduction of severity and
duration of acute attacks. The benefit of self administra-
tion of prophylactic C1-inh would decrease cost and
allow the patient significant flexibility to travel and
administer therapy at the most suitable time. The current
dosage recommended by the FDA for routine prophylaxis
is 1000 units intravenously every 3-4 days and would
require significant time and inconvenience to the patient
if this had to be administered solely by a health profes-
sional.
Two studies have shown that select patients may bene-
fit tremendously from self-administration of C1 esterase
inhibitor and with self-treatment are able to improve
quality of life [14]. These 9 patients were experiencing
severe and frequent attacks of HAE. Their quality of life
was assessed before and after 3 to 48 months of self-
administered therapy. The QOL was assessed using the
Dermatology Life Quality Index (DLQI) and the 36 Item
Short form Survey questionnaires. The mean DLQI fellDagen and Craig Allergy, Asthma & Clinical Immunology 2010, 6:11
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significantly from 12.6 +/- 4.65 to 2.7 +/- 1.38. The mean
for the Short Form survey also improved significantly. No
adverse events occurred during the 3-year period of
intravenous self-administration [14].
In addition to affecting positively the patient's quality of
life, one study also investigated whether self-administra-
tion was feasible and safe for the patients. Levi et al exam-
ined 31 patients using C1-inh as an "on demand"
treatment and 12 patients using C1-inh prophylactically.
Both groups were able to successfully administer the con-
centrate with a failure rate of less than 2%. During self
administration attacks decreased from 4.0 to 0.3 per
month in the group using prophylactic C1INH, but also
self administration significantly decreased time to relief
onset in those patients using it on demand for acute
attacks [15]. This study not only confirmed the efficacy of
self administered intravenous C1INH both as on demand
treatment and as prophylactic therapy, but also demon-
strated that patient administration is a viable and safe
option. A manuscript published our manuscript further
investigates self-infusion therapy and outlines the tech-
nique, quality assurance, training and reassessment of
patients' prescribed self-infusion at home.
Unless peripheral access is limited, indwelling central
catheters should be avoided due to the adverse events
associated with port-o-catheters and similar devices. The
most common complications of central lines include
mechanical complications, infections and thrombotic
events. Adverse events associated with indwelling central
catheters are listed in appendix 4 [16].
Unfortunately, ecallantide has not been approved in the
USA for home nor self-administration. The surveillance
program required by the FDA for ecallantide limits its use
to the clinic, and should be given by a health care pro-
vider who is capable of treating anaphylaxis, since ana-
phylaxis is a rare side effect of ecallantide. Dyax is hoping
that the post-marketing surveillance program will dem-
o n s t r a t e  t h e  s a f e t y  o f  e ca l l a n t i d e  a l l o wi n g  i t  t o  be  s e l f
administered by the patient at home via the subcutaneous
route.
Icatibant is presently repeating phase 3 studies in the
USA and is anticipating approval for self-administration
by the subcutaneous route. The drug is stable at room
temperature and this combined with approval of icatibant
for self subcutaneous injection will provide significant
flexibility for patients with HAE to travel, camp, hike and
do other recreational activities. It is projected that icati-
bant will be approved in the USA in 2012.
Discussion
The treatment of acute attacks and prophylactic treat-
ment of HAE has been evolving. In the recent past, the
treatment of acute attacks was largely supportive, with
hydration, pain relief and close observation as the main-
Figure 1 Ability to predict HAE attacks based on prodromal symptoms. This bar graph demonstrates the percentage of individuals with HAE who 
are able to predict an HAE attack based on prodromal symptoms based on the study by Prematta in 2009. 6.5% of patient are able to predict the onset 
of an attack 100% of the time, 50% are able to predict an attack 75% of the time, 8.7% are able to predict an attack 50% of the time and 26.1% are able 
to predict an attack 25% of the time. Only 8.7% are unable to predict their attacks at all.Dagen and Craig Allergy, Asthma & Clinical Immunology 2010, 6:11
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stays of treatment. FFP has also been used, but does pres-
ent increased risk for viral transmission as compared with
C1-inh, and there have been anecdotal reports of exacer-
bations of an acute attack when FFP is given for treat-
ment; however, it appears this is a very infrequent
occurrence [6].
For prophylactic treatment, therapy has largely
revolved around androgens, particularly danazol. How-
ever, as discussed previously, danazol has a negative side
effect profile, which makes it intolerable for some
patients. Other treatments, such as kallikrein inhibitors
and bradykinin antagonists, are unlikely to be effective
for prophylaxis due to their short half-lives. Antifibrin-
olytics are limited by their adverse effect profile.
Fortunately so nf-C1-inh is now available for use as
prophylactic therapy. It is approved for 1000 U every 3-4
days, but due to breakthrough attacks, higher doses are
being investigated to see if better control can be achieved.
Even with breakthrough attacks, it appears that regular
use of C1-inh reduces the severity and duration of the
breakthrough attacks. This prophylactic regimen,
although it has a less negative side effect profile than dan-
azol, has a high cost and requires intravenous administra-
tion. Using a health professional for infusions can be
quite time consuming, frustrating and inconvenient for
the patient. The concept of self-administration has been
also proven reasonable and effective, but would require
correct patient selection and teaching.
Currently, on demand C1-inh (ODT) has also been
proven safe and efficacious when used at the onset of a
facial or abdominal attack. However, since it is used at the
onset of an attack, multiple disadvantages for the patient
still exist, such as pain and lost of work or school. C1-inh
has been used successfully for 30 years in Europe as ODT
for acute HAE attacks has been shown to be safe and
effective and is the preferred therapy in Europe at this
time [17].
For future therapy, the idea of ODT, would allow treat-
ment based on prodromal symptoms experienced by the
patients. As discussed in the text, up to 50% of individuals
Figure 2 Time between onset of prodromal symptoms and their next HAE attack. This bar graph demonstrates the timing of acute attacks after 
the onset of prodromal symptoms. 45.5% of all patients had an attack within 24 hours of a prodromal symptom and 54.5% reported that their attack 
came 24 hours after the onset of the prodromal symptoms. However, the majority reported an attack within the first 12 hours after the onset of the 
prodromal symptom.Dagen and Craig Allergy, Asthma & Clinical Immunology 2010, 6:11
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can predict 75% of their attacks based on prodromal
symptoms. Although some selection bias may have been
introduced in this study, as those who do have prodromal
symptoms may have been more likely to respond, the data
still demonstrate a significant portion of people who
could benefit from ODT. These prodromal symptoms, be
it fatigue, rash or muscle aches, are often followed by an
attack, usually within hours to days. This would allow
patients who do experience prodromal symptoms to pre-
emptively treat themselves in the hopes that it would pre-
vent an imminent attack and the symptoms that cause
pain, disfigured appearance and even death. Although
this method could lead to the occasional over treatment,
it would hopefully lead to decreased morbidity and a bet-
ter quality of life. The effectiveness of ecallantide and
icatibant, both short acting therapies, for prodromal
symptoms needs to be assessed, but we anticipate effi-
cacy.
As evident from our results self-administration is a key
feature for patients to treat and control their disease. Sub-
cutaneous injection is obviously preferred over intrave-
nous therapy as the technique is easily taught and the
adverse events associated with poor technique are mini-
mal. This is in contrast to intravenous therapy where
guidelines are needed for teaching, assuring quality and
infection prevention via continual evaluation, in addition
to preventing other adverse outcomes that may occur
with intravenous lines. Adverse events associated with
indwelling central lines are far greater and more likely
associated with significant morbidity and possible mor-
tality and because of this should be avoided unless access
peripherally is severely compromised (see appendix 4)
[16].
Both acute and prophylactic treatment of HAE has
been changing since the approval and introduction of C1-
inh concentrate in the USA. Although currently approved
for both acute and prophylactic treatment of HAE, the
idea of ODT for use of prodromal symptoms may
broaden the use of C1-inh. Currently, cost and its admin-
istration route are drawbacks of C1-inh, but many studies
have already shown that self-administration is feasible
and safe as long as proper candidates are selected. The
multiple advances in prophylactic treatment and therapy
for those suffering from HAE are exciting and may repre-
sent a better quality of life for those individuals suffering
from repeated attacks. With the hopeful prospect of ODT
for prodromal symptoms, HAE attacks may become
more infrequent still and can help these individuals main-
tain control over their disease and lead an attack free life.
Appendixes
Appendix 1
Modified from Craig et al, Annals of Allergy asthma and
Immunology, 2009 [5]
Candidates for long-term prophylaxis. Individuals who
suffer from the listed consequences of their HAE and
hence have a diminished quality of life are candidates for
prophylaxis with C1-inh.
Those deemed candidates for long-term prophylaxis
with C-1 Esterase Inhibitor.
-Those with significant anxiety
-Those with more than 1 attack per month
-Previous intubation or ICU stay
-Previous laryngeal swelling
-Those with more than 10 days lost from school or
work per year
-A significantly decreased QOL
-Narcotic dependence
-Those with limited access to healthcare or with rapid
onset of attacks
Appendix 2
Modified from Craig et al, Proceeding of Allergy and
Asthma, 2007
Adverse Effects of Danazol [6]
Adverse events associated with danazol. This appendix
demonstrates the numerous adverse events associated
with long-term administration of the attenuated andro-
gen, danazol. These multiple side effects often lead to
noncompliance or discontinuation of the drug.
-Weight gain
-Virilization
-Menstrual irregularities
-Depression
-Headache
-Abnormal LFTs
-Negative effect on lipid profiles
-Cardiac and vascular disease
-Liver disease including hepatic cell necrosis, cholesta-
sis, hepatocellular adenoma and hepatocellular carci-
noma
-The need to follow LFTs, lipid panels, and liver imag-
ing
Appendix 3
Adapted from Nentwich, Intravenous Therapy, 1990 [13]
Procedure for Self-Infusing of C-1 Esterase inhibitor
Procedure for self-administration of IV medications.
The necessary procedure that must be demonstrated in
order to be able to successfully self-administer IV medi-
cations is listed. Careful selection of the proper patient is
essential in order to ensure compliance.
Patient must demonstrate the following technique
1. Cleanse skin with alcohol and betadine
2. Prepare medication in aseptic technique
3. Apply tourniquet
4. Insert butterflyDagen and Craig Allergy, Asthma & Clinical Immunology 2010, 6:11
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5. With blood splash, inject saline to keep line patent
and remove tourniquet
6. Tape needle down
7. Infuse drug over 10-20 minutes
8. Complete all steps with aseptic techniques
9. Remove needle when complete
10. Apply pressure for a few minutes
11. Bandage area
Appendix 4
Modified from McGee et al NEJM, 2003 [16]
Adverse events associated with indwelling central cath-
eters. Indwelling catheters are associated with many sig-
nificant adverse events, some which can be life
threatening.
Adverse events associated with indwelling central cath-
eters and other similar devices
-Arterial puncture
-Hematoma
-Pneumothorax**
-Infection
-Thrombosis
**Depends on site of insertion
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